Logo for Cogent Biosciences Inc

Cogent Biosciences Inc Investor Relations Material

Latest events

Logo for Cogent Biosciences Inc

Study Update

Cogent Biosciences Inc
Logo for Cogent Biosciences Inc

Q1 2025

6 May, 2025
Logo for Cogent Biosciences Inc

Q4 2024

25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Cogent Biosciences Inc

Access all reports
Cogent Biosciences Inc. is a biotechnology company focused on the development of precision therapies for genetically defined diseases. The company's lead product, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting mutations in the KIT receptor tyrosine kinase. These mutations are critical in conditions such as systemic mastocytosis and advanced gastrointestinal stromal tumors. Cogent Biosciences holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.